vimarsana.com
Home
Live Updates
BridgeBio Pharma Shares Positive Long-Term Data from an Ongo
BridgeBio Pharma Shares Positive Long-Term Data from an Ongo
BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
- Early assessment of increased glycosylated ⍺DG levels at 3 months predicted subsequent ambulatory improvements at 9 months, supporting the use of glycosylated ⍺DG levels as a potential surrogate...
Related Keywords
Australia ,
United Kingdom ,
Charleston ,
South Carolina ,
United States ,
Tamy Harper ,
Douglas Sproule ,
Vikram Bali ,
Virginia Commonwealth University ,
Ml Bio Solutions ,
World Muscle Society ,
Drug Administration ,
Nasdaq ,
Linkedin ,
Bridgebio Pharma Inc ,
Bio Pharma Inc ,
Securities Exchange ,
Twitter ,
North Star Assessment ,
Accelerated Approval ,
Bio Pharma ,
Annual Congress ,
Limb Girdle Muscular Dystrophy Type ,
Bridgebio Pharma ,
Securities Act ,
Securities Exchange Act ,
Accelerated Approval Pathway ,
Risk Factors ,
Annual Report ,
Bio Media Contact ,
Markets ,